QIAGEN and Intradigm Initiate Collaboration Targeting siRNA Applications
Jul 08 2003

QIAGEN and Intradigm Initiate Collaboration Targeting siRNA Applications

Venlo, The Netherlands and Rockville, Maryland, July 8, 2003 - QIAGEN N.V. (Nasdaq: QGENF; Frankfurt, Prime Standard: QIA), the leading provider of innovative products for nucleic acid handling, separation and purification, as well as synthetic nucleic acid products, and Intradigm Corporation, a leader in RNAi in vivo delivery technology, have entered into an agreement providing for research and development of siRNA for drug discovery and siRNA therapeutic products. QIAGEN will manufacture and provide Intradigm with siRNA agents for its ongoing research programs in several disease areas, including oncology, arthritis, and pulmonary siRNA treatment of SARS Coronavirus infection. Financial terms were not disclosed.

QIAGEN has a leading position in siRNA synthesis technology using patented TOM-Amidite chemistry to produce HPP (High Performance Purity) Grade siRNA for efficient gene silencing. QIAGEN is a licensed supplier of siRNA, offering custom high throughput siRNA oligonucleotide synthesis services and a large library of predeveloped siRNA molecules directed against common target genes which includes the SARS Coronavirus siRNA Set specific for the human coronavirus.

Intradigm has developed systemic and local siRNA delivery technologies for knocking down disease genes in animals and has validated the therapeutic potentials of siRNA agents for treatment of cancer, viral infection and other unmet clinical needs. Using effective airway delivery of siRNA duplexes specific to SARS Coronavirus, a single stranded RNA virus, may represent a novel approach to treat the deadly infection. Using at least 48 sets of siRNA oligos to be designed by Intradigm and QIAGEN and manufactured by QIAGEN, Intradigm will determine optimal siRNA agents and delivery to inhibit SARS viral infection as potential anti-SARS therapy through work with collaborators in National Institute of Allergy and Infectious Diseases (NIAID) of USA and in Hong Kong and Guangzhou of China.

"We are pleased that Intradigm has chosen QIAGEN as its collaboration and supply partner for its research programs targeting siRNA-based therapeutics," said Dr. Ulrich Schriek, QIAGEN's Vice President of Corporate Business Development. "Intradigm's systemic and local delivery technologies for siRNA place them on the cutting edge of the development of RNA-based therapeutics."

John Spears, Chairman and CEO of Intradigm said, "We are very excited about this relationship with QIAGEN, one of the world leaders in siRNA oligo manufacturing. We believe there is vast potential for RNAi-based therapeutics and are looking forward to working with QIAGEN as we identify appropriate siRNA candidates for further development".

About QIAGEN

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,600 people worldwide. Further information on QIAGEN can be found at www.qiagen.com.

About Intradigm Corporation

Intradigm Corporation is a privately held Delaware corporation that is discovering and developing therapeutic products by applying proprietary in vivo RNAi delivery technologies. Intradigm's Efficacy-First Discovery and Validation method is based on extensive nucleic acid delivery capabilities that, when combined with RNAi and animal disease models, provide rapid and effective discovery and validation of drug targets giving efficacy in clinically relevant disease models. Intradigm has a growing portfolio of novel targets for cancer therapeutics and associated candidate therapeutic agents including antibodies, small molecules, and RNAi. Investors include Emerging Technology Partners, Novartis Venture Fund and the State of Maryland's Business and Economic Development Department. Intradigm is located in the Association for Entrepreneurial Sciences Inc. facilities in Rockville, MD. Further information on Intradigm can be found at http://www.intradigm.com/.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

Contacts:

Peer M. Schatz
Chief Financial Officer
QIAGEN N.V.
+49 2103 2911 702
e-mail: peer.schatz@QIAGEN.com

Dr. Solveigh Mähler
Manager Investor Relations
QIAGEN N.V.
+49 2103 2911 710
e-mail: solveigh.maehler@QIAGEN.com

Dr. Ulrich Schriek
VP Corporate Business Development
QIAGEN GmbH
+49 2103 29 11238
e-mail: ulrich.schriek@QIAGEN.com

FOLLOW US ON SOCIAL MEDIA

Share this page